MedTrace Logo

Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD

NCT00624481 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2008-03-13

No results posted yet for this study

Summary

This study is being conducted to compare the effect of increasing nasal teriparatide dosing on percent change in Bone Mineral Density (BMD) of the lumbar spine after 24 weeks of therapy in postmenopausal women with low bone mineral density.

Conditions

Interventions

DRUG

Teriparatide

20ug subcutaneous injection daily for 24 weeks

DRUG

Teriparatide Nasal Spray

teriparatide intranasally daily for 24 weeks

DRUG

Teriparatide Nasal Spray

teriparatide intranasally daily for 24 weeks

DRUG

Teriparatide Nasal Spray

teriparatide intranasally daily for 24 weeks

DRUG

Teriparatide Nasal Spray

teriparatide intranasally daily for 24 weeks

Sponsors & Collaborators

  • Nastech Pharmaceutical Company, Inc.

    lead INDUSTRY

Principal Investigators

  • Gordon Brandt, MD · Nastech Pharmaceutical Company, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
89 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-04-30
Completion
2009-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00624481 on ClinicalTrials.gov